Norges Bank
ADAP

Norges Bank’s Adaptimmune Therapeutics ADAP Stock Holding History

Norges Bank’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-40,000
Closed -$733K – 2281
2015
Q2 		$733K Buy
+40,000
New +$686K ﹤0.01% 2155

Other funds holding ADAP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Norges Bank's ADAP Position: Q3 2015 in Review

Norges Bank sold out of Adaptimmune Therapeutics (ADAP) in Q3 2015, closing a stake of 40,000 shares — an estimated $733K sold.

Norges Bank first reported a position in ADAP in Q2 2015 and held it in 1 quarter. The position peaked at $733K in Q2 2015. 41 funds tracked by Wall St. Rank hold ADAP as of Q3 2015.

  • Norges Bank reported no remaining Adaptimmune Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Norges Bank sold 40,000 Adaptimmune Therapeutics shares in Q3 2015, an estimated $733K.
  • Norges Bank first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 1 quarter.
  • Norges Bank's Adaptimmune Therapeutics position peaked at $733K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2015.

Based on Norges Bank's 13F filing for Q3 2015, filed 6 Nov 2015.